May 2025: Key Moves in MedTech & Life Sciences

May 2025 MedTech & Life Sciences Updates

From billion-dollar acquisitions, strategic partnerships and approvals, the Medical & Life Sciences landscape is constantly shifting and 2025 is already proving to be no exception. As a team of recruiters deeply embedded in this space, we keep a close eye on the partnerships, mergers, and innovations that are shaping the future of healthcare.

Each month, we’ll be highlighting some of the latest news across the Medical and Life Science fields. Whether you’re a biotech exec, healthcare specialist, or just a market watcher, these updates aim to keep you informed and ahead of the curve.

Here’s a round-up of some of the standout announcements across Medical & Life Sciences in May:

• GSK to acquire Boston Pharmaceutical’s lead asset efimosfermin alfa. GSK will pay $1.2 billion initially, with additional milestone payments possible,e totalling $800 million

• Sanofi are set to acquire Vigil Neuroscience, a publicly traded biotech developing novel therapies for neurodegenerative diseases, after investing $40 million in June 2024. The acquisition will include outstanding common shares of Vigil with an approximate equity value of $470 million

• Waters Corp. has acquired Halo Labs, a business specialising in imaging technologies for the detection, identification and counting of particles in therapeutic products. 

• Regeneron Pharmaceuticals plans to acquire genomics company 23andMe’s core assets for $256 million through a bankruptcy auction

• Qiagen announced it’s agreement to acquire Genoox, a provider of AI-powered software enabling the scale and acceleration of processing complex genetic tests, for $70 million in cash and potential milestone payments up to $10 million

• Mapmygenome, an AI-based genomics and personalised health solutions provider, has acquired Microbiome Insights, a Canadian microbial sequencing company, helping them tap into the North American market

• Fujirebio Diagnostics received the green light from the FDA for their blood test to diagnose Alzheimer’s Disease, the first device of its kind to receive a 510(k) clearance

• Teal Health, a women’s health aiming to eliminate cervical cancer, has received FDA approval for the Teal Wand, the first and only at-home vaginal sample self-collection device for cervical cancer screening in the US

• Hyalex Orthopaedics Inc received FDA approval for IDE expansion for it’s Freestyle Knee Implant

• Merit Medical Systems has acquired Biolife Delaware, a haemostatic device manufacturer for $120 million

• Firefly Neuroscience acquires Evoke Neuroscience,  a company focused on developing technology to assess brain health, bringing key assets including a database of over 180,000 standardised records of EEG/ERP assessments

• PCI Pharma Services, a leading global CDMO, is to acquire Ajinomoto Althea, a US-based sterile fill-finish CDMO and subsidiary of Ajinomoto Co. Inc

• Distalmotion, a global MedTech in robotic surgery, announced it has received FDA 510(k) clearance for the use of its DEXTER® Robotic Surgery System in adult cholecystectomy

• CRISPR Therapeutics announced its collaboration with Sirius Therapeutics to develop and commercialise siRNA therapies, with Sirius set to receive $25 million in cash upfront and $70 million in equity

• Danaher Corporation, launched a partnership with AstraZeneca to develop and commercialise novel diagnostic tools and tests to determine which patients would benefit from precision medicines

Whether it's expanding into new therapeutic frontiers, deepening platform capabilities, or accelerating innovation through strategic partnerships, these deals tell a story of where the industry is heading.

If you're navigating change, looking to grow your team, exploring new opportunities, or just interested in what’s happening in the industry, feel free to contact our team.